Oncology and Hematology - Global Oncology Academy

Episodes 241-256 of 532

Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Hadfield, MD
From Diagnosis to Treatment: Challenges in Glioblastoma Care
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care
- Lauren Schaff, MD
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
1.00 credit 10 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 10 episodes
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CE
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
0.50 credits
- Elizabeth R. Plimack, MD, MS, FASCO
- Shilpa Gupta, MD
0.50 credits
Screening Modalities for Colon Cancer: What You Need to Know
Screening Modalities for Colon Cancer: What You Need to Know
Global Oncology Academy
Screening Modalities for Colon Cancer: What You Need to Know
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Project Oncology®
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Project Oncology®
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credit
- Daniel P. Petrylak, MD
- Elizabeth R. Plimack, MD, MS, FASCO
- Evan Y. Yu, MD
1.00 credit
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Project Oncology®
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Project Oncology®
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
Project Oncology®
Advancing Multiple Myeloma Treatment: The Role of Immunotherapy and Personalized Care
- Shaji K. Kumar, MD

16/11